Erythropoietin drugs are protein therapeutics, which is used to treat various types of anaemia. These drugs play a significant role in treating CKD related anaemia and cancer related anaemia. Since its inception, the erythropoietin drugs market has witnessed various technological advancements, which have resulted in development of more effective and long acting EPO drugs. Launch of biosimilars in the erythropoietin market has increased its affordability. European region is the largest market for erythropoietin biosimilar, which makes it a major market for over all erythropoietin drugs as well. As per RNCOS report "European Erythropoietin Market Outlook 2022", the market of Europe was valued at US$ 1.4 Billion in 2015. This report provides a detailed analysis of the current and future market scenario of the European erythropoietin market. The report highlights biosimilar erythropoietin at various stages of clinical development. In addition, the report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. Based on segment, the report sub-divides the market into biologics and biosimilar. Currently, biologics hold major share in the European market. However, biosimilar market is poised to witness the highest growth due to their cost effectiveness. Based on country, the report segments the market into Germany, France, UK, Italy, and Spain. The report provides detailed analysis of each country. Moreover, the report also provides the market for various types of EPO (alpha, beta, and darbepoetin alpha amongst other) for each country. Furthermore, the report covers the prevalence and incidences of CKD and cancer for each country under application segmentation. Additionally, the report also provides the patent analysis and pipeline analysis of erythropoietin market. The last section of the report discusses about the prominent players in European erythropoietin market. A brief business overview and financial information about each of these players has been provided along with their product portfolios. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the European erythropoietin market.
Table of Contents 1. Analyst View 2. Research Methodology 3. European Protein Therapeutics Market 3.1 Protein Therapeutics Market Vs Pharmaceutical Market 3.2 Current and Future Market Analysis for 2022 3.3 Market Segmentation 4. Erythropoietin Market - Introduction 5. European Erythropoietin Market Outlook 2022 5.1 By Segment 5.1.1 Biologics 5.1.2 Biosimilar 6. European Erythropoietin Market by Country Outlook 2022 6.1 France 6.1.1 Market Size 6.1.2 By Segment 6.1.3 By Type 6.1.4 By Application 6.2 Italy 6.2.1 Market Size 6.2.2 By Segment 6.2.3 By Type 6.2.4 By Application 6.3 Germany 6.3.1 Market Size 6.3.2 By Segment 6.3.3 By Type 6.3.4 By Application 6.4 Spain 6.4.1 Market Size 6.4.2 By Segment 6.4.3 By Type 6.4.4 By Application 6.5 UK 6.5.1 Market Size 6.5.2 By Segment 6.5.3 By Type 6.5.4 By Application 7. Patents and R&D Pipeline Analysis 8. Market Dynamics 8.1 Drivers 8.1.1 Rising Focus on Developing Biosimilars in the Region 8.1.2 Use of Innovative Technologies for EPO Development 8.1.3 Rising Number of Elderly People 8.1.4 Growth in Chronic Diseases Incidences 8.1.5 Growing Pressure to Reduce Healthcare Expenditure in the Region 8.2 Challenges 8.2.1 Expensive Biologics 8.2.2 Side-Effects of EPO 8.2.3 Threat of Subsitute for CKD Anemia 9. Key Players Analysis 9.1 Amgen Inc. 9.1.1 Business Overview 9.1.2 Product Portfolio 9.1.3 Financial Overview 9.2 Johnson & Johnson 9.2.1 Business Overview 9.2.2 Product Portfolio 9.2.3 Financial Overview 9.3 Roche Group 9.3.1 Business Overview 9.3.2 Products Portfolio 9.3.3 Financial Overview 9.4 Pfizer Inc. 9.4.1 Business Overview 9.4.2 Product Portfolio 9.4.3 Financial Overview 9.5 Novartis 9.5.1 Business Overview 9.5.2 Product Portfolio 9.5.3 Financial Overvie 9.6 Teva Pharmaceuticals Ltd. 9.6.1 Business Overview 9.6.2 Products Portfolio 9.6.3 Financial Overview 9.7 Stada Arzneimittel AG 9.7.1 Business Overview 9.7.2 Products Portfolio 9.7.3 Financial Overview 9.8 Sanofi 9.8.1 Business Overview 9.8.2 Products Portfolio 9.8.3 Financial Overview 9.9 3SBio Inc. 9.9.1 Business Overview 9.9.2 Products Portfolio 9.10 Dr. Reddy's Laboratories 9.10.1 Business Overview 9.10.2 Products Portfolio 9.10.3 Financial Overview
List of Tables: Table 6-1: Erythropoietin Market of France by Type (Million US$), 2015 & 2022 Table 6-2: Erythropoietin Market of Italy by Type (Million US$), 2015 & 2022 Table 6-3: Erythropoietin Market of Germany by Type (Million US$), 2015 & 2022 Table 6-4: Erythropoietin Market of Spain by Type (Million US$), 2015 & 2022 Table 6-5: Erythropoietin Market of UK by Type (Million US$), 2015 & 2022 Table 7-1: Erythropoietin Patent Analysis of Europe Table 7-2: Erythropoietin Product Pipeline Table 9-1: Amgen Inc. - Commercialized EPO Products Table 9-2: Amgen Inc. - Financials (Billion US$), 2013, 2014 & 2015 Table 9-3: Amgen Inc. - EPO Product Sales (Billion US$), 2013, 2014 & 2015 Table 9-4: Johnson & Johnson - Commercialized EPO Products Table 9-5: Johnson & Johnson - Financials (Billion US$), 2013, 2014 & 2015 Table 9-6: Johnson & Johnson - EPO Product Sales (Billion US$), 2013, 2014 & 2015 Table 9-7: Roche - Commercialized EPO Products Table 9-8: Roche - Financials (Billion US$), 2013, 2014 & 2015 Table 9-9: Roche - Europe EPO Product Sales (Billion US$), 2013, 2014 & 2015 Table 9-10: Pfizer Inc. - Commercialized EPO Products Table 9-11: Pfizer Inc. - Financials (Billion US$), 2013, 2014 & 2015 Table 9-12: Novartis - Commercialized EPO Products Table 9-13: Novartis - Financials (Billion US$), 2013, 2014 & 2015 Table 9-14: Teva Pharmaceuticals Ltd. - Commercialized EPO Products Table 9-15: Teva Pharmaceuticals Ltd. - Financials (Billion US$), 2013, 2014 & 2015 Table 9-16: Stada - Commercialized EPO Products Table 9-17: Stada - Financials (Billion US$), 2013, 2014 & 2015 Table 9-18: Sanofi - Commercialized EPO Products Table 9-19: Sanofi - Financials (Billion US$), 2013, 2014 & 2015 Table 9-20: 3SBio Inc. - Commercialized EPO Products Table 9-21: Dr. Reddy's Laboratories - Commercialized EPO Products Table 9-22: Dr. Reddy's Laboratories - Financials (Billion US$), 2013, 2014, & 2015
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.